Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, University Hospital, Palacký University Olomouc, Olomouc, Czech Republic.
Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, University Hospital, Palacký University Olomouc, Olomouc, Czech Republic.
J Med Virol. 2021 Jun;93(6):3871-3879. doi: 10.1002/jmv.26520. Epub 2020 Oct 7.
BK polyomavirus-associated nephropathy (PyVAN) is responsible for a significant percentage of transplanted kidneys prematurely terminating their function. Its occurrence is closely related to the intensity of immunosuppressive therapy. In a group of 161 newly transplanted patients, we prospectively evaluated 457 protocol renal biopsies performed within the first year after transplantation. Using the calcineurin inhibitors (CI) nephrotoxicity score, the incidence of nephrotoxicity was monitored as a manifestation of excessive immunosuppression. Findings were correlated with clinical evidence of active BK polyomavirus (BKPyV) replication and PyVAN. Compared to the normal histology, nephrotoxicity was associated with more frequent BKPyV viremia and viruria (p = .01 and p < .01, respectively) and more common occurrence of PyVAN. The persistence of toxicity in the subsequent biopsy proved to be a negative risk factor of viremia and viruria (p = .03 and p < .01, respectively), independently of the initial BKPyV status. Toxicity could also be used as a predictor of viremia and viruria (p = .04 and p < .01, respectively) even in the absence of viral replication at the time of initial biopsy. The early histological manifestation of CI nephrotoxicity was associated with significant BKPyV reactivation in the risky first posttransplant year.
BK 多瘤病毒相关性肾病 (PyVAN) 可导致相当一部分移植肾脏提前丧失功能,其发生与免疫抑制治疗的强度密切相关。在 161 名新移植患者中,我们前瞻性评估了移植后 1 年内进行的 457 次协议性肾活检。采用钙调磷酸酶抑制剂 (CI) 肾毒性评分监测肾毒性作为过度免疫抑制的表现。将结果与 BK 多瘤病毒 (BKPyV) 复制和 PyVAN 的临床证据相关联。与正常组织学相比,肾毒性与更频繁的 BKPyV 血症和尿病毒载量(p =.01 和 p <.01)以及更常见的 PyVAN 相关。随后活检中持续存在毒性被证明是病毒血症和尿病毒载量的负面风险因素(p =.03 和 p <.01),与初始 BKPyV 状态无关。即使在初始活检时没有病毒复制,毒性也可用作病毒血症和尿病毒载量的预测因素(p =.04 和 p <.01)。CI 肾毒性的早期组织学表现与移植后风险较高的第一年中 BKPyV 的显著再激活相关。